Is HYPERTENSION a side effect of SORAFENIB (RAF KINASE INHIBITOR) ? ( FactMed.com )

About this FactMed analysis covering adverse side effect reports of SORAFENIB (RAF KINASE INHIBITOR) patients who developed HYPERTENSION.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 160 individuals taking SORAFENIB (RAF KINASE INHIBITOR) reported HYPERTENSION to the FDA. A total of 3329 SORAFENIB (RAF KINASE INHIBITOR) drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between SORAFENIB (RAF KINASE INHIBITOR) and HYPERTENSION. In doing so, we compare SORAFENIB (RAF KINASE INHIBITOR) with other drugs that cause HYPERTENSION, to help you evaluate whether or not SORAFENIB (RAF KINASE INHIBITOR) causes HYPERTENSION. Likewise, this page shows the most highly-reported side effects of SORAFENIB (RAF KINASE INHIBITOR), so you can see if HYPERTENSION ranks among SORAFENIB (RAF KINASE INHIBITOR)'s most well-known side effects.

Summary Statistics
Reports of SORAFENIB (RAF KINASE INHIBITOR) causing HYPERTENSION: 160
Reports of any side effect of SORAFENIB (RAF KINASE INHIBITOR) : 3329
Percentage of SORAFENIB (RAF KINASE INHIBITOR) patients where HYPERTENSION is a reported side effect: 4.8062%

FDA reports of any drug causing HYPERTENSION : 70385
Average percentage for all medicated patients where HYPERTENSION is reported as a complication: 0.4411%

Physician opinion on SORAFENIB (RAF KINASE INHIBITOR) as adverse event culprit:

Overall opinion for all reports of this drug:

Most frequent diagnoses/indications for prescribing SORAFENIB (RAF KINASE INHIBITOR):

HEPATIC NEOPLASM MALIGNANT ( 770 patients )
RENAL CELL CARCINOMA ( 114 patients )
THYROID CANCER ( 65 patients )
METASTATIC RENAL CELL CARCINOMA ( 44 patients )
THYROID CANCER METASTATIC ( 35 patients )
BREAST CANCER ( 31 patients )
BREAST CANCER METASTATIC ( 27 patients )
GASTRIC CANCER ( 25 patients )
NON-SMALL CELL LUNG CANCER ( 25 patients )
COLORECTAL CANCER METASTATIC ( 22 patients )
RENAL CANCER ( 17 patients )
PRODUCT USED FOR UNKNOWN INDICATION ( 14 patients )
BILE DUCT CANCER ( 14 patients )
SALIVARY GLAND CANCER ( 7 patients )
HEPATIC CANCER METASTATIC ( 7 patients )
COLORECTAL CANCER ( 7 patients )
SMALL CELL LUNG CANCER STAGE UNSPECIFIED ( 6 patients )
RECTAL CANCER ( 5 patients )
PANCREATIC CARCINOMA ( 4 patients )
PROSTATE CANCER ( 4 patients )
INTRAOCULAR MELANOMA ( 4 patients )
HEPATIC NEOPLASM MALIGNANT RECURRENT ( 3 patients )
NEOPLASM ( 3 patients )
LIVER DISORDER ( 3 patients )
ANGIOSARCOMA ( 3 patients )
NON-SMALL CELL LUNG CANCER STAGE IV ( 3 patients )
METASTASES TO LUNG ( 3 patients )
HEPATIC NEOPLASM MALIGNANT NON-RESECTABLE ( 3 patients )
COLORECTAL CANCER STAGE IV ( 3 patients )
NEOPLASM MALIGNANT ( 3 patients )
GALLBLADDER CANCER METASTATIC ( 3 patients )
BILIARY CANCER METASTATIC ( 3 patients )
METASTASIS ( 3 patients )
COLON CANCER METASTATIC ( 2 patients )
HYPOPHARYNGEAL CANCER ( 2 patients )
DESMOID TUMOUR ( 2 patients )
NEUROENDOCRINE CARCINOMA ( 2 patients )
ACUTE MYELOID LEUKAEMIA (IN REMISSION) ( 2 patients )
LUNG NEOPLASM MALIGNANT ( 2 patients )
OESOPHAGEAL CARCINOMA ( 2 patients )
METASTATIC MALIGNANT MELANOMA ( 2 patients )
TONGUE NEOPLASM MALIGNANT STAGE UNSPECIFIED ( 2 patients )
METASTATIC SQUAMOUS CELL CARCINOMA ( 2 patients )
ANGINA PECTORIS ( 2 patients )
RENAL CELL CARCINOMA STAGE IV ( 2 patients )
OSTEOSARCOMA METASTATIC ( 2 patients )
BONE SARCOMA ( 2 patients )
METASTATIC OCULAR MELANOMA ( 2 patients )
METASTATIC SALIVARY GLAND CANCER ( 2 patients )
TONSIL CANCER ( 2 patients )
MYELODYSPLASTIC SYNDROME ( 1 patients )
PROSTATE CANCER METASTATIC ( 1 patients )
GALLBLADDER CANCER ( 1 patients )
NEUROENDOCRINE TUMOUR ( 1 patients )
MALIGNANT NEOPLASM OF RENAL PELVIS ( 1 patients )
GLIOMA ( 1 patients )
BLADDER CANCER ( 1 patients )
OVARIAN CANCER METASTATIC ( 1 patients )
CAROTID ARTERY DISEASE ( 1 patients )
HEPATOBLASTOMA ( 1 patients )
NASOPHARYNGEAL CANCER ( 1 patients )
ACUTE MYELOID LEUKAEMIA ( 1 patients )
LUNG ADENOCARCINOMA ( 1 patients )
RENAL CANCER METASTATIC ( 1 patients )
DIFFUSE LARGE B-CELL LYMPHOMA ( 1 patients )
NEUROENDOCRINE CARCINOMA OF THE SKIN ( 1 patients )
MALIGNANT HISTIOCYTOSIS ( 1 patients )
ANTICOAGULANT THERAPY ( 1 patients )
MALIGNANT SOFT TISSUE NEOPLASM ( 1 patients )
SARCOMA ( 1 patients )
GERM CELL CANCER ( 1 patients )
OESOPHAGEAL ADENOCARCINOMA ( 1 patients )
SQUAMOUS CELL CARCINOMA ( 1 patients )
HEAD AND NECK CANCER ( 1 patients )
OVARIAN EPITHELIAL CANCER ( 1 patients )
( 0 patients )

Drugs with high FDA adverse event association with HYPERTENSION:

VIOXX (18821 patients)
FOSAMAX (12928 patients)
ASPIRIN (7401 patients)
SEROQUEL (4280 patients)
LIPITOR (3935 patients)
LISINOPRIL (3360 patients)
LASIX (3194 patients)
PREDNISONE (2778 patients)
NEXIUM (2772 patients)
NEXAVAR (2751 patients)
AVONEX (2689 patients)
ZOMETA (2615 patients)
SYNTHROID (2604 patients)
ATENOLOL (2550 patients)
NORVASC (2484 patients)
CELEBREX (2414 patients)
HYDROCHLOROTHIAZIDE (2411 patients)
ZYPREXA (2378 patients)
DIOVAN (2302 patients)
TOPROL-XL (2194 patients)
NEURONTIN (2186 patients)
FUROSEMIDE (2149 patients)
ZOCOR (2078 patients)
PLAVIX (2070 patients)
XANAX (1988 patients)
ZOLOFT (1983 patients)
PRILOSEC (1955 patients)
OMEPRAZOLE (1891 patients)
AMBIEN (1864 patients)
COUMADIN (1862 patients)
PROTONIX (1812 patients)
DIGOXIN (1797 patients)
METHOTREXATE (1797 patients)
HEPARIN SODIUM INJECTION (1777 patients)
AVANDIA (1683 patients)
PREMARIN (1647 patients)
FOLIC ACID (1627 patients)
SIMVASTATIN (1625 patients)
REMICADE (1600 patients)
PREVACID (1598 patients)
ACETAMINOPHEN (1566 patients)
LYRICA (1533 patients)
PAXIL (1526 patients)
AREDIA (1494 patients)
CYMBALTA (1490 patients)
PREDNISOLONE (1481 patients)
HUMIRA (1472 patients)
ALBUTEROL (1453 patients)
ALENDRONATE SODIUM (1357 patients)
VICODIN (1346 patients)
LORAZEPAM (1334 patients)
LEVOTHYROXINE SODIUM (1301 patients)
IBUPROFEN (1295 patients)
POTASSIUM CHLORIDE (1277 patients)
FOSAMAX PLUS D (1274 patients)
METFORMIN HCL (1267 patients)
AMLODIPINE (1246 patients)
DURAGESIC-100 (1222 patients)
CRESTOR (1205 patients)
ATIVAN (1202 patients)
LEVAQUIN (1198 patients)
PROZAC (1172 patients)
METOPROLOL TARTRATE (1164 patients)
[THERAPY UNSPECIFIED] (1161 patients)
LEXAPRO (1130 patients)
EFFEXOR (1122 patients)
CLONIDINE (1115 patients)
PERCOCET (1114 patients)
LANTUS (1113 patients)
COREG (1113 patients)
OXYCONTIN (1087 patients)
GABAPENTIN (1051 patients)
ENBREL (1043 patients)
FORTEO (1042 patients)
VITAMIN D (1028 patients)
NITROGLYCERIN (1025 patients)
INSULIN (1025 patients)
ALLOPURINOL (998 patients)
ACCUTANE (971 patients)
COZAAR (965 patients)
AVASTIN (958 patients)
GLUCOPHAGE (957 patients)
CLONAZEPAM (950 patients)
TYLENOL (CAPLET) (938 patients)
CALCIUM (UNSPECIFIED) (936 patients)
DEXAMETHASONE (929 patients)
CHANTIX (925 patients)
SUTENT (923 patients)
ZANTAC (917 patients)
ALPRAZOLAM (908 patients)
LOPRESSOR (901 patients)
WELLBUTRIN (897 patients)
METOPROLOL (894 patients)
ADVAIR DISKUS 100/50 (888 patients)
LORTAB (883 patients)
WARFARIN SODIUM (874 patients)
REBIF (874 patients)
RISPERDAL (865 patients)
PREDNISONE TAB (854 patients)
CELEXA (831 patients)
ALLEGRA (827 patients)
BEXTRA (826 patients)
FLEXERIL (816 patients)
ZOFRAN (812 patients)
CALCIUM (797 patients)
ZYRTEC (790 patients)
DIAZEPAM (785 patients)
DIOVAN HCT (782 patients)
MORPHINE (778 patients)
SINGULAIR (775 patients)
ACTONEL (768 patients)
VITAMINS (UNSPECIFIED) (768 patients)
TYSABRI (766 patients)
BONIVA (759 patients)
SPIRIVA (751 patients)
HUMALOG (744 patients)
CYCLOSPORINE (737 patients)
DECADRON (737 patients)
VALIUM (729 patients)
RAMIPRIL (727 patients)
AMOXICILLIN (719 patients)
MULTI-VITAMINS (709 patients)
ACTOS (707 patients)
ASCORBIC ACID (707 patients)
ENALAPRIL MALEATE (702 patients)
ALTACE (692 patients)
TYLENOL (684 patients)
SPIRONOLACTONE (676 patients)
SANDOSTATIN LAR (671 patients)
METFORMIN (661 patients)
ZESTRIL (661 patients)
GLYBURIDE (653 patients)
ULTRAM (651 patients)
KLONOPIN (651 patients)
OXYCODONE HCL (641 patients)
TRAMADOL HCL (640 patients)
NAPROXEN (631 patients)
DEPAKOTE (626 patients)
TRAZODONE HCL (626 patients)
VITAMIN E (623 patients)
RANITIDINE (623 patients)
CLOZARIL (616 patients)
COLACE (614 patients)
EFFEXOR XR (611 patients)
FENTANYL (609 patients)
CARVEDILOL (606 patients)
CARDIZEM (606 patients)
VIAGRA (603 patients)
HYDROCODONE BITARTRATE (602 patients)
LOVENOX (600 patients)
ATACAND (592 patients)
CALCIUM CARBONATE (589 patients)
METOPROLOL SUCCINATE (586 patients)
FLONASE (581 patients)
REGLAN (574 patients)
GLIPIZIDE (571 patients)
PEPCID (569 patients)
ARANESP (569 patients)
PREMPRO (563 patients)
NEORAL (559 patients)
ZITHROMAX (558 patients)
BENADRYL (556 patients)
BACLOFEN (555 patients)
KLOR-CON (554 patients)
CLARITIN (553 patients)
PROMETHAZINE (553 patients)
PROGRAF (552 patients)
FLUOROURACIL (545 patients)
ABILIFY (535 patients)
ZETIA (534 patients)
TENORMIN (534 patients)
BEVACIZUMAB (531 patients)
ACCUPRIL (531 patients)
MULTI-VITAMIN (530 patients)
PRAVACHOL (525 patients)
METHYLPREDNISOLONE (524 patients)
VERAPAMIL (516 patients)
NIFEDIPINE (512 patients)
CEPHALEXIN (510 patients)
CIPROFLOXACIN (509 patients)
ELAVIL (508 patients)
CYCLOPHOSPHAMIDE (502 patients)
VITAMIN D (UNSPECIFIED) (502 patients)
DIANEAL (500 patients)
AMITRIPTYLINE HCL (498 patients)
TEMAZEPAM (492 patients)
LANSOPRAZOLE (490 patients)
FAMOTIDINE (487 patients)
ARIMIDEX (485 patients)
AMARYL (484 patients)
HEPARIN (484 patients)
DILAUDID (481 patients)
BACTRIM (481 patients)
FEMARA (480 patients)
COMPAZINE (480 patients)
FERROUS SULFATE TAB (474 patients)
ACIPHEX (470 patients)
POTASSIUM (469 patients)
ALDACTONE (467 patients)
AVAPRO (465 patients)
VANCOMYCIN (460 patients)
CLINDAMYCIN (460 patients)
REVLIMID (460 patients)
PROCRIT (459 patients)
METOCLOPRAMIDE (457 patients)
PRINIVIL (457 patients)
CITALOPRAM HYDROBROMIDE (457 patients)
PANTOPRAZOLE (456 patients)
MOTRIN (450 patients)
COMBIVENT (449 patients)

Most common side effects for patients taking SORAFENIB (RAF KINASE INHIBITOR):

DIARRHOEA (613 patients)
HEPATIC FAILURE (378 patients)
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME (342 patients)
HEPATIC ENCEPHALOPATHY (320 patients)
FATIGUE (300 patients)
RASH (276 patients)
ASCITES (253 patients)
ABDOMINAL PAIN (237 patients)
DECREASED APPETITE (226 patients)
UPPER GASTROINTESTINAL HAEMORRHAGE (198 patients)
PYREXIA (191 patients)
ASPARTATE AMINOTRANSFERASE INCREASED (179 patients)
NAUSEA (165 patients)
HYPERTENSION (160 patients)
ASTHENIA (154 patients)
DEHYDRATION (140 patients)
HEPATIC FUNCTION ABNORMAL (133 patients)
DYSPNOEA (131 patients)
CONFUSIONAL STATE (131 patients)
HYPOKALAEMIA (125 patients)
ALOPECIA (124 patients)
VOMITING (118 patients)
CONSTIPATION (115 patients)
INTERSTITIAL LUNG DISEASE (114 patients)
LEFT VENTRICULAR DYSFUNCTION (113 patients)
DEATH (113 patients)
ENDOCARDITIS (112 patients)
ARTHRALGIA (111 patients)
STOMATITIS (111 patients)
ABDOMINAL PAIN UPPER (110 patients)
JAUNDICE (108 patients)
HEPATIC NEOPLASM MALIGNANT (106 patients)
GASTROINTESTINAL HAEMORRHAGE (106 patients)
RETINAL VASCULAR THROMBOSIS (103 patients)
LOWER GASTROINTESTINAL HAEMORRHAGE (103 patients)
LIVER CARCINOMA RUPTURED (101 patients)
OEDEMA PERIPHERAL (97 patients)
PLEURAL EFFUSION (97 patients)
STAPHYLOCOCCAL INFECTION (96 patients)
PNEUMONIA BACTERIAL (96 patients)
ENTEROBACTER INFECTION (96 patients)
MYOPATHY (95 patients)
DRY MOUTH (94 patients)
PAIN IN EXTREMITY (93 patients)
ANXIETY (90 patients)
MALAISE (89 patients)
PULMONARY EMBOLISM (85 patients)
ANAEMIA (84 patients)
PLATELET COUNT DECREASED (81 patients)
BACK PAIN (79 patients)
SEPSIS (78 patients)
PRURITUS (78 patients)
DUODENAL ULCER (77 patients)
MIGRAINE (76 patients)
MITRAL VALVE INCOMPETENCE (76 patients)
HYPOGLYCAEMIA (76 patients)
C-REACTIVE PROTEIN INCREASED (74 patients)
BLOOD PRESSURE INCREASED (73 patients)
VARICES OESOPHAGEAL (73 patients)
HEADACHE (72 patients)
RETINAL VEIN OCCLUSION (72 patients)
ABASIA (69 patients)
RENAL FAILURE ACUTE (69 patients)
WEIGHT DECREASED (67 patients)
DEEP VEIN THROMBOSIS (67 patients)
DIZZINESS (65 patients)
ERYTHEMA (65 patients)
GENERAL PHYSICAL HEALTH DETERIORATION (64 patients)
CONVULSION (63 patients)
ALANINE AMINOTRANSFERASE INCREASED (62 patients)
DYSPHONIA (62 patients)
CEREBRAL HAEMORRHAGE (60 patients)
APHAGIA (58 patients)
COLITIS (58 patients)
PNEUMONIA (57 patients)
GASTRIC ULCER (56 patients)
HYPONATRAEMIA (55 patients)
HAEMOGLOBIN DECREASED (53 patients)
RESPIRATORY FAILURE (52 patients)
LUNG DISORDER (52 patients)
CEREBRAL ISCHAEMIA (49 patients)
PARAESTHESIA (49 patients)
BLOOD BILIRUBIN INCREASED (48 patients)
GAIT DISTURBANCE (48 patients)
THYROID CANCER METASTATIC (44 patients)
DEPRESSED LEVEL OF CONSCIOUSNESS (43 patients)
PERICARDIAL EFFUSION (41 patients)
THROMBOCYTOPENIA (41 patients)
BLISTER (41 patients)
FEBRILE NEUTROPENIA (40 patients)
BLOOD LACTATE DEHYDROGENASE INCREASED (40 patients)
HALLUCINATION (40 patients)
CHILLS (40 patients)
AMMONIA INCREASED (39 patients)
SKIN ULCER (39 patients)
BLOOD ALKALINE PHOSPHATASE INCREASED (38 patients)
PAIN (38 patients)
HYPOALBUMINAEMIA (38 patients)
HYPOCALCAEMIA (37 patients)
FALL (37 patients)
POLLAKIURIA (37 patients)
BLOOD PRESSURE DECREASED (37 patients)
SKIN EXFOLIATION (37 patients)
INSOMNIA (36 patients)
CARDIAC ARREST (36 patients)
HYPOAESTHESIA (35 patients)
INFECTIOUS PERITONITIS (35 patients)
MYOCARDIAL INFARCTION (35 patients)
RETINAL VASCULAR DISORDER (34 patients)
RENAL FAILURE (34 patients)
LIPASE INCREASED (34 patients)
HYPERKALAEMIA (33 patients)
HYPERGLYCAEMIA (33 patients)
HAEMOPTYSIS (31 patients)
ATRIAL FIBRILLATION (30 patients)
GENERALISED OEDEMA (30 patients)
FAECAL INCONTINENCE (30 patients)
WHITE BLOOD CELL COUNT DECREASED (30 patients)
CELLULITIS (29 patients)
CHEST PAIN (29 patients)
SOMNOLENCE (29 patients)
HYPERBILIRUBINAEMIA (28 patients)
HYPOTENSION (28 patients)
MUSCLE SPASMS (28 patients)
ABDOMINAL DISTENSION (27 patients)
WHITE BLOOD CELL COUNT INCREASED (27 patients)
VISION BLURRED (27 patients)
HEPATIC PAIN (26 patients)
BLOOD ALBUMIN DECREASED (26 patients)
DYSURIA (25 patients)
RASH GENERALISED (25 patients)
BLOOD SODIUM DECREASED (25 patients)
BLOOD URIC ACID INCREASED (25 patients)
COMA (25 patients)
COUGH (25 patients)
PANCYTOPENIA (25 patients)
ACUTE ABDOMEN (24 patients)
EOSINOPHIL COUNT INCREASED (24 patients)
CEREBROVASCULAR ACCIDENT (24 patients)
METASTASES TO CENTRAL NERVOUS SYSTEM (23 patients)
CEREBRAL INFARCTION (23 patients)
HYPOMAGNESAEMIA (23 patients)
RETINAL VEIN THROMBOSIS (23 patients)
GAMMA-GLUTAMYLTRANSFERASE INCREASED (23 patients)
TUMOUR LYSIS SYNDROME (22 patients)
HYPOPHOSPHATAEMIA (22 patients)
INFECTION (22 patients)
ORAL PAIN (22 patients)
BLOOD CREATININE INCREASED (22 patients)
NEUTROPENIA (22 patients)
RENAL IMPAIRMENT (22 patients)
LETHARGY (22 patients)
SKIN TOXICITY (21 patients)
TONGUE BLISTERING (21 patients)
LIVER ABSCESS (21 patients)
HAEMATEMESIS (21 patients)
OESOPHAGEAL VARICES HAEMORRHAGE (20 patients)
MENTAL IMPAIRMENT (20 patients)
NERVOUSNESS (20 patients)
NEPHROTIC SYNDROME (20 patients)
HYPOPHAGIA (20 patients)
ADRENAL INSUFFICIENCY (19 patients)
DRY SKIN (19 patients)
BLOOD AMYLASE INCREASED (19 patients)
OEDEMA (19 patients)
INFECTIOUS PLEURAL EFFUSION (19 patients)
DYSPEPSIA (19 patients)
COMA HEPATIC (19 patients)
HEART RATE INCREASED (18 patients)
HYPERTENSIVE CRISIS (18 patients)
MYALGIA (18 patients)
ECZEMA (18 patients)
URINARY TRACT INFECTION (18 patients)
NEUROMYOPATHY (18 patients)
MEDICAL DEVICE COMPLICATION (18 patients)
DIVERTICULITIS (18 patients)
OSTEOMYELITIS (18 patients)
CEREBRAL ATROPHY (18 patients)
CEREBRAL VENTRICLE DILATATION (18 patients)
DIABETIC FOOT INFECTION (18 patients)
NECK PAIN (18 patients)
OLIGURIA (17 patients)
GASTROINTESTINAL DISORDER (17 patients)
HAEMATOCHEZIA (17 patients)
DISSEMINATED INTRAVASCULAR COAGULATION (17 patients)
HYPOTHYROIDISM (17 patients)
TRANSAMINASES INCREASED (17 patients)
OROPHARYNGEAL PAIN (17 patients)
CHRONIC MYELOID LEUKAEMIA (17 patients)
NEOPLASM PROGRESSION (17 patients)
METASTASES TO ADRENALS (16 patients)
LYMPHOCYTE COUNT DECREASED (16 patients)
INTERNATIONAL NORMALISED RATIO INCREASED (16 patients)
MULTI-ORGAN FAILURE (16 patients)
FEAR (16 patients)
PANCREATIC CARCINOMA (16 patients)
HYPERSOMNIA (16 patients)
EPILEPSY (16 patients)
SUBARACHNOID HAEMORRHAGE (16 patients)
METASTASES TO LUNG (16 patients)
TACHYCARDIA (16 patients)
MUSCULAR WEAKNESS (16 patients)
KLEBSIELLA SEPSIS (16 patients)
MYOCARDIAL ISCHAEMIA (16 patients)
DYSGEUSIA (16 patients)
LUNG INFECTION (16 patients)
FAECES DISCOLOURED (16 patients)
PAIN OF SKIN (16 patients)
SPINAL FRACTURE (16 patients)
PANIC REACTION (16 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.

Recent FactMed Activity for SORAFENIB (RAF KINASE INHIBITOR)

Issue	Description / Topic	Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about HYPERTENSION and SORAFENIB (RAF KINASE INHIBITOR), post it here. You may receive a response from a fellow patient - or a leading expert in the field.

Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking SORAFENIB (RAF KINASE INHIBITOR), post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.

Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in SORAFENIB (RAF KINASE INHIBITOR). This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.

We are currently accepting registration for SORAFENIB (RAF KINASE INHIBITOR) experts. If you are a healthcare provider experienced in prescribing SORAFENIB (RAF KINASE INHIBITOR), please register here.